Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous ConjunctivitisFunding None.
30 January 2020
08 March 2020
05 May 2020 (online)
Background Ligneous conjunctivitis (LC) is a rare disorder associated with plasminogen deficiency characterized by chronic fibrin deposits in the eyelids. All patients with plasminogen deficiency do not develop LC, whose underlying mechanisms remain unknown.
Objective We investigated whether fibrinolytic activity was correlated with phenotype and/or genotype in patients suffering from LC and their relatives.
Methods Plasminogen activity/antigen levels and PLG mutations were determined in 10 patients with LC, 17 of their asymptomatic relatives, and 10 healthy individuals used as a control group. Plasma fibrinolytic activity was evaluated using three different assays: (1) tissue-plasminogen activator (t-PA) front lysis, (2) cell-based urokinase-dependent euglobulin clot lysis (ECLT) at the surface of corneal cells, and (3) urokinase-dependent plasminogen activation.
Results Plasminogen activity varied from <10 to 40% in patients, 36 to 105% in relatives, and >80% in control healthy individuals. Homozygous K19E mutation was associated with normal antigenic plasminogen levels. In front-lysis experiments, all patients had a lower fibrinolysis rate as compared with their relatives and to control individuals. The cell-based ECLT and plasminogen activation assay demonstrated that urokinase-mediated fibrinolysis was not impaired in patients with homozygous K19E mutation compared with the other mutants.
Conclusion We confirm that plasminogen levels fail to predict LC occurrence. In these conditions, t-PA clot lysis front is useful to predict clinical outcome in plasminogen deficiency. Moreover, we provide evidence that occurrence of LC overlaps quantitative and qualitative plasminogen deficiencies. The homozygous K19E mutation is associated with isolated impaired t-PA-mediated fibrinolysis compared with other mutants.
- 1 Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol 2003; 48 (04) 369-388
- 2 Mingers AM, Heimburger N, Zeitler P, Kreth HW, Schuster V. Homozygous type I plasminogen deficiency. Semin Thromb Hemost 1997; 23 (03) 259-269
- 3 Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007; 5 (12) 2315-2322
- 4 Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129 (03) 307-321
- 5 Romer J, Bugge TH, Pyke C. , et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2 (03) 287-292
- 6 Kawao N, Tamura Y, Okumoto K. , et al. Plasminogen plays a crucial role in bone repair. J Bone Miner Res 2013; 28 (07) 1561-1574
- 7 Celkan T. Plasminogen deficiency. J Thromb Thrombolysis 2017; 43 (01) 132-138
- 8 Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9 (07) 794-807
- 9 Ramsby ML, Donshik PC, Makowski GS. Ligneous conjunctivitis: biochemical evidence for hypofibrinolysis. Inflammation 2000; 24 (01) 45-71
- 10 Tefs K, Gueorguieva M, Klammt J. , et al. Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. Blood 2006; 108 (09) 3021-3026
- 11 Klammt J, Kobelt L, Aktas D. , et al. Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. Thromb Haemost 2011; 105 (03) 454-460
- 12 Siboni SM, Spreafico M, Menegatti M, Martinelli I, Peyvandi F. Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. Blood Coagul Fibrinolysis 2007; 18 (01) 81-84
- 13 Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90 (04) 428-434
- 14 Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112 (5-6): 329-337
- 15 Martin-Fernandez L, Marco P, Corrales I. , et al. The unravelling of the genetic architecture of plasminogen deficiency and its relation to thrombotic disease. Sci Rep 2016; 6: 39255
- 16 Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RAS. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107 (18) 2326-2330
- 17 Suntharalingam J, Goldsmith K, van Marion V. , et al. Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 2008; 31 (04) 736-741
- 18 Okamoto A, Sakata T, Mannami T, Baba S. , et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in Japanese: the Suita Study. J Thromb Haemost 2003; 1 (11) 2397-2403
- 19 Shapiro AD, Nakar C, Parker JM. , et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood 2018; 131 (12) 1301-1310
- 20 Schuster V, Zeitler P, Seregard S. , et al. Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost 2001; 85 (06) 1004-1010
- 21 Cockell CS, Marshall JM, Dawson KM, Cederholm-Williams SA, Ponting CP. Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide. Biochem J 1998; 333 (Pt 1): 99-105
- 22 Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost 2018; 16 (04) 652-662
- 23 Dejouvencel T, Doeuvre L, Lacroix R. , et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115 (10) 2048-2056
- 24 Watanabe M, Yano W, Kondo S. , et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci 2003; 44 (08) 3332-3338
- 25 Ilich A, Noubouossie DF, Henderson M. , et al. Development and application of global assays of hyper- and hypofibrinolysis. Res Pract Thromb Haemost 2019; 4 (01) 46-53
- 26 Saes JL, Schols SEM, Betbadal KF. , et al. Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency. Haemophilia 2019; 25 (06) 1073-1082
- 27 Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev 2015; 29 (01) 17-24
- 28 Mingers AM, Philapitsch A, Schwarz HP, Zeitler P, Kreth HW. Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis. Semin Thromb Hemost 1998; 24 (06) 605-612
- 29 Mingers AM, Philapitsch A, Zeitler P, Schuster V, Schwarz HP, Kreth HW. Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. APMIS 1999; 107 (01) 62-72